ArticleDiagnostic pathology2016
EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Article in Diagnostic pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches.International journal of molecular sciences · 2024Pooled it
- Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02).Breast (Edinburgh, Scotland) · 2026Trial
- SOX-2 and EZH-2 Expression in Primary Epithelial Malignant Salivary Gland Tumors.Medical sciences (Basel, Switzerland) · 2026Article
- Human Cytomegalovirus Infection and Breast Cancer: A Literature Review of Clinical and Experimental Data.Biology · 2025Review
- Cellular Transformation by Human Cytomegalovirus.Cancers · 2024Article
- Tumor-suppressive functions of protein lysine methyltransferases.Experimental & molecular medicine · 2023Review
- Fibrin Stiffness Regulates Phenotypic Plasticity of Metastatic Breast Cancer Cells.Advanced healthcare materials · 2023Article
- Article
- EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis.Nature communications · 2022Article
- Polyploid giant cancer cells, EZH2 and Myc upregulation in mammary epithelial cells infected with high-risk human cytomegalovirus.EBioMedicine · 2022Article
- EZH2-CCF-cGAS Axis Promotes Breast Cancer Metastasis.International journal of molecular sciences · 2022Article
- Downregulation of histone-lysine N-methyltransferase EZH2 inhibits cell viability and enhances chemosensitivity in lung cancer cells.Oncology letters · 2021Article
- Clinicopathologic significance of protein lysine methyltransferases in cancer.Clinical epigenetics · 2020Review
- COCOA: coordinate covariation analysis of epigenetic heterogeneity.Genome biology · 2020Article
- Article
- Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2020Article
- Discovery of a first-in-class EZH2 selective degrader.Nature chemical biology · 2020Article
- USP7 deubiquitinates and stabilizes EZH2 in prostate cancer cells.Genetics and molecular biology · 2020Article
- NF-κB/NKILA signaling modulates the anti-cancerous effects of EZH2 inhibition.Journal of cellular and molecular medicine · 2019Article
- Inhibition of enhancer of zeste homolog 2 increases the expression of p16 and suppresses the proliferation and migration of ovarian carcinoma cellsOncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnhancer of zest homolog 2 (EZH2), a histone 3 methyltransferase, is associated with aggressive behavior of many tumors and is a promising target of molecular therapy.
methodsTo better elucidate the relevance of EZH2 in breast cancer subtypes, we evaluated EZH2 expression in 226 invasive breast carcinomas with four distinct immunophenotypes and in association with clinicopathological features.
resultsOf these cases, 138 (61.1 %) were defined as EZH2-overexpressing with a multiplicative score > 3. EZH2 expression was inversely related to the status of ER and PR (Chi-square, p < 0.001), and it was significantly associated with HER2 positivity, high proliferative index, and high histologic grade (Chi-square, p < 0.05). ER-positive breast carcinoma with low proliferative index (Ki67 < 14 %) showed the lowest expression and triple-negative breast carcinoma showed the highest overexpression of EZH2, 18.5 % (10/54) versus 90.9 % (50/55) (Chi-square, p < 0.001). Intriguingly, 88 % (44/50) cases of grade 3 triple-negative breast carcinoma showed uniformly strong EZH2 expression with a multiplicative score of 9. The percentage of EZH2 overexpression in ER-positive breast carcinoma with a high proliferative index or HER2-positive cases were 61.2 and 74 %, respectively. Furthermore, EZH2 expression was significantly elevated in high-grade DCIS compared to benign lesions (90 % versus 0, p < 0.001). However, there is no association between EZH2 expression and the status of histone 3 lysine 27 trimethylation or other clinicopathologic features.
conclusionIn summary, triple-negative breast carcinoma showed the highest overexpression of EZH2. EZH2 overexpression is associated aggressive pathologic features including high nuclear grade, high proliferative index, and positivity of HER2 of breast carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.